

AMENDMENTS TO THE CLAIMS

I. Listing of the Claims: This Listing will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method for assessing risk of a neurodegenerative disease or disorder associated with amyloidosis in a subject, which method comprises:

determining ~~comparing~~ a level of anti- β -amyloid-42 ($A\beta_{42}$) antibody in a biological sample selected from the group consisting of blood, serum, plasma and cerebral spinal fluid from a subject,

comparing the level of anti- $A\beta_{42}$ antibody in the biological sample from the subject to a normal level determined from the level of anti- $A\beta_{42}$ antibody in a biological sample from a population consisting of age-matched normal subjects who do not show any symptoms of neurodegenerative disease or disorder associated with amyloidosis, wherein a lower level in the biological sample from the subject indicates the risk-~~presence~~ of a neurodegenerative disease or disorder associated with amyloidosis.

~~2.-4. (Canceled)~~

5. (Original) The method according to claim 1, which comprises determining the level of anti- $A\beta_{42}$ antibody in the biological sample by immunoassay.

6. (Original) The method according to claim 5, wherein the immunoassay is an enzyme-linked immunosorbent assay.

7. (Original) The method according to claim 1, wherein assessing risk is diagnosing.

8. (Currently amended) The method according to claim 2 ~~1~~, wherein the subject is from a family that has a member or members with familial Alzheimer's Disease.

9. (Currently amended) The method according to claim 1, wherein the subject is in his or her seventh or ~~eight~~ eighty decade of life.

10. (Currently Amended) A method for assessing risk of Alzheimer's Disease in a subject, which method comprises:

determining ~~comparing~~ a level of anti- β -amyloid-42 ($A\beta_{42}$) antibody in a biological sample selected from the group consisting of blood, serum, plasma and cerebral spinal fluid from a subject,

comparing the level of anti- $A\beta_{42}$ antibody in the biological sample from the subject to a normal level determined from the level of anti- $A\beta_{42}$ antibody in a biological sample from a population of age-matched normal subjects who do not show any symptoms of Alzheimer's Disease, wherein a lower level in the biological sample from the subject indicates the risk presence of Alzheimer's Disease.

11.-13. (Canceled)

14. (Currently amended) The method according to claim 10, which comprises determining the level of anti ~~amyloid peptide~~ $A\beta_{42}$ antibody in the biological sample by immunoassay.

15. (Original) The method according to claim 10, wherein the subject is from a family that has a member or members with familial Alzheimer's Disease.

16. (Currently amended) A method for assessing risk of Alzheimer's Disease in a subject, which method comprises:

~~determining~~ ~~comparing~~ a level of anti- β -amyloid-42 ($A\beta_{42}$) antibody in a biological sample selected from the group consisting of blood, serum, plasma and cerebral spinal fluid from a subject, wherein the subject does not exhibit symptoms of cognitive dysfunction or memory dysfunction,

comparing a level of anti- $A\beta_{42}$ antibody in a biological sample, ~~wherein the subject does not exhibit symptoms of cognitive dysfunction or memory dysfunction from a subject to~~ a normal level determined from the level of anti- $A\beta_{42}$ antibody in a biological sample from a population consisting of age-matched normal subjects who do not show any symptoms of associated with Alzheimer's Disease, wherein a lower level in the biological sample from the subject indicates the risk ~~presence~~ of Alzheimer's Disease.

~~17.~~ (Currently amended) The method according to claim 16.2, wherein the subject is from a family that has a member or members with familial Alzheimer's Disease.

18. (Currently amended) The method according to claim 16, wherein the subject is in his or her seventh or eighth decade of life.

19.-26. (Canceled)

27. (Currently amended) The method according to claim 14, wherein the normal level is determined from an average of the level of anti-~~amyloid-peptide~~ A β ₄₂ antibody in the biological sample from a population of age-matched normal subjects who do not show any symptoms of the Alzheimer's Disease.

28.-30. (Canceled)